Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (W81XWH2110376)
National Institutes of Health (R01CA169604, R35CA264619)
- License Information
-
More Information
Article History
Received: 16 March 2022
Accepted: 1 August 2022
First Online: 8 August 2022
Declarations
:
: E. L. receives research funding for preclinical ovarian cancer studies from Abbvie and Arsenal Bioscience outside of the scope of this work and is co-inventor on a patent proposing to use FABP inhibitors for ovarian cancer treatment. A. M. and A. J. B. have no conflicts to report.
